NEO
Q4 2026 EPS Estimate
$0.06
Oct 27, 2026
Revenue Estimate
$206M
FY2026E EPS$0.18
FY2027E EPS$0.34

Analyst Sentiment

Wall St. Consensus
Buy
29 analysts·High coverage
70
Score
23 Buy (79%)5 Hold (17%)1 Sell (4%)
Rating Breakdown
Strong Buy
13%
Buy
2276%
Hold
517%
Sell
13%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$13.00
-19.9%
Consensus
$19.00
+17.1%
Bull
$25.00
+54.0%
12-Month Target Range29 analysts
$13.00$19.00$25.00
Current $16.23Consensus
Current Price
$16.23
Upside to Consensus
$2.77

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+10.03%
EPS+85.07%
FY2028
Rev+9.13%
EPS+36.89%
FY2029
Rev+6.57%
EPS+49.05%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$804M$885M$966M$1.03B$1.11B
Low$801M$883M$952M$1.02B$1.10B
High$806M$889M$977M$1.04B$1.12B
EBITDA Avg$-24M$-27M$-29M$-31M$-34M
Low$-24M$-27M$-29M$-31M$-34M
High$-24M$-27M$-29M$-31M$-33M
EBIT Avg$-116M$-128M$-140M$-149M$-161M
Low$-116M$-128M$-141M$-150M$-162M
High$-116M$-128M$-138M$-148M$-159M
Net Income Avg$4M$9M$13M$18M$21M
Low$4M$7M$1M$17M$21M
High$5M$10M$24M$18M$21M
EPS Avg$0.18$0.34$0.46$0.69$0.81
Low$0.14$0.29$0.05$0.68$0.80
High$0.19$0.38$0.94$0.70$0.82
Analysts (Rev / EPS)9 / 79 / 76 / 54 / 13 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$206M$210M$207M$221M$225M$230M$224M$242M
Low$204M$208M$205M$219M$223M$228M$222M$240M
High$207M$211M$208M$222M$226M$231M$225M$243M
EBITDA Avg$-6M$-6M$-6M$-7M$-7M$-7M$-7M$-7M
Low$-6M$-6M$-6M$-7M$-7M$-7M$-7M$-7M
High$-6M$-6M$-6M$-7M$-7M$-7M$-7M$-7M
EBIT Avg$-30M$-30M$-30M$-32M$-33M$-33M$-32M$-35M
Low$-30M$-31M$-30M$-32M$-33M$-33M$-33M$-35M
High$-30M$-30M$-30M$-32M$-32M$-33M$-32M$-35M
Net Income Avg$1M$2M$2M$2M$2M$3M$2M$3M
Low$842,070$1M$2M$2M$2M$3M$2M$3M
High$2M$2M$2M$2M$2M$3M$2M$3M
EPS Avg$0.05$0.07$0.06$0.09$0.09$0.10$0.08$0.13
Low$0.03$0.05$0.06$0.09$0.09$0.10$0.08$0.13
High$0.08$0.10$0.06$0.09$0.09$0.10$0.09$0.13
Analysts (Rev / EPS)7 / 77 / 73 / 23 / 23 / 26 / 55 / 64 / 5

Earnings Surprises

Recent Analyst Actions

Jul 29, 2026Craig-Hallum
NeoGenomics price target raised to $19 from $17 at Craig-Hallum
Target:$19.00
+20.4%from $15.79
Apr 29, 2026Leerink Partners
Leerink upgrades NeoGenomics to Outperform, raises target to $25
Target:$25.00
+177.2%from $9.02
Feb 24, 2026Piper Sandler
NeoGenomics price target raised to $13 from $12 at Piper Sandler
Target:$13.00
+30.4%from $9.97
Oct 28, 2025Leerink Partners
NeoGenomics price target raised to $14 from $12 at Leerink
Target:$14.00
+41.1%from $9.92
Sep 2, 2025Stephens
NeoGenomics price target raised to $11 from $6.50 at Stephens
Target:$11.00
+24.9%from $8.81
Aug 4, 2025Piper Sandler
NeoGenomics price target lowered to $11 from $12 at Piper Sandler
Target:$11.00
+94.0%from $5.67
Jul 30, 2025Morgan Stanley
NeoGenomics price target lowered to $8 from $10 at Morgan Stanley
Target:$8.00
+56.9%from $5.10
Jul 29, 2025Needham
Neogenomics (NEO) PT Lowered to $8 at NeedhamMember Login
Target:$8.00
+52.4%from $5.25
May 6, 2025Piper Sandler
NeoGenomics price target lowered to $12 from $18 at Piper Sandler
Target:$12.00
+53.1%from $7.84
Jan 11, 2025BTIG
NeoGenomics price target lowered to $18 from $21 at BTIG
Target:$18.00
+21.9%from $14.77
Jul 30, 2024Needham
Needham Reiterates Buy Rating on Neogenomics (NEO)
Target:$19.00
+29.8%from $14.64
May 2, 2024BTIG
Neogenomics (NEO) PT Lowered to $21 at BTIG
Target:$21.00
+50.4%from $13.96
Aug 21, 2023Stephens
Stephens Upgrades Neogenomics (NEO) to Overweight
Target:$18.00
+27.8%from $14.08
Aug 17, 2022Piper Sandler
NeoGenomics price target raised to $19 from $13 at Piper Sandler
Target:$19.00
+63.2%from $11.64
Aug 10, 2022Morgan Stanley
Morgan Stanley Maintains Equal-Weight on NeoGenomics, Lowers Price Target to $18
Target:$18.00
+54.4%from $11.66
Aug 10, 2022Goldman Sachs
Goldman Sachs Maintains Buy on NeoGenomics, Raises Price Target to $20
Target:$20.00
+72.6%from $11.59
Aug 10, 2022Needham
Needham Maintains Buy on NeoGenomics, Lowers Price Target to $16
Target:$16.00
+37.0%from $11.68
Apr 28, 2022Raymond James
Raymond James Maintains Outperform on NeoGenomics, Lowers Price Target to $15
Target:$15.00
+43.7%from $10.44
Jun 3, 2021Goldman Sachs
NeoGenomics initiated with a Buy at Goldman Sachs
Target:$55.00
+37.1%from $40.11
May 25, 2021Guggenheim
NeoGenomics price target lowered to $54 from $65 at Truist
Target:$54.00
+37.9%from $39.17
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.